Innocrin Pharmaceuticals Initiates Phase 2 Study of Seviteronel in Women with Difficult-to-Treat Breast Cancer

Innocrin Pharmaceuticals Initiates Phase 2 Study of Seviteronel in Women with Difficult-to-Treat Breast Cancer
Innocrin Pharmaceuticals has initiated dosing in a Phase 2 clinical trial in patients with estrogen receptor-positive (ER+) or triple negative breast cancer (TN BCa) to determine the safety, tolerability, pharmacokinetics and activity of seviteronel (VT-464), a lyase-selective inhibitor of CYP17. After completion of the Phase 1 part of trial, a once-daily dose was chosen for Phase 2 development. A diagnosis of triple negative breast cancer means that the three most common types of receptors known to fuel most breast cancer growth–estrogen, progesterone, and the HER-2/neu gene — are not present in the cancer tumor.  This means that the breast cancer cells have tested negative for hormone epidermal growth factor receptor 2 (HER-2), estrogen receptors (ER), and progesterone receptors (PR).  Since the tumor cells lack the necessary receptors, common treatments like hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.  Patients with triple-negative breast cancer might respond well to anti-androgen therapies. Seviteronel selectively inhibits CYP17 lyase, a target of abiraterone, and has unique blocking effects on androgen receptor (AR), the target of enzalutamide. Preclinical and clinical data has shown that some abiraterone- or enzalutamide-resistant patients will respond to seviteronel treatment. The drug is being developed for the treatment of breast and prostate cancers resistant to traditional anti-hormonal therapy. William Moore, Ph.D., Innocrin’s Chief Executive Officer said in a
Subscribe or to access all post and page content.